Dr. Goldfarb has special interests in the treatment of children with end-stage lung disease such as cystic fibrosis, interstitial lung disease, pulmonary late effects of oncology treatments, and other pulmonary disorders.
Dr. Rheingold's research interests center on acute lymphocytic leukemia, and she serves on the Children's Oncology Group's Relapsed ALL, Infant ALL, and Complementary Therapies committees. In addition, she is investigates complementary and alternative therapies, supportive care for oncology patients undergoing chemotherapy, medical education, and rare childhood tumors.
Dr. Schwartz's research focuses on behavioral and psychosocial aspects of cancer and its treatment in adolescents and young adults (AYAs), a group of patients with unique medical and psychosocial challenges. Most of her current studies aim to understand and improve self-management among AYAs.
Dr. Resnick's research focuses on the cell signaling mechanisms of oncogenesis and tumor progression in brain tumors. He studies signaling cascades and alterations to elucidate the molecular and genetic underpinnings in order to develop targeted therapies. As co-director of the Center of Data-Driven Discovery in Biomedicine, he leads a multidisciplinary team building and supporting a scalable, patient-focused healthcare and educational discovery ecosystem.
Dr. Thomas-Tikhonenko has a long-standing interest in the pathobiology of solid and hematopoietic malignancies, in particular lymphomas and leukemias and other cancers driven by MYC overexpression. Within that research space, his studies focus mainly (but not exclusively) on RNA-based regulatory mechanisms, such as microRNAs and alternative mRNA splicing.
Dr. Bauer's academic and clinical career are focused on improving the care of children and adolescents with thyroid disease. He has extensive experience and knowledge of thyroid pathophysiology and tumorigenesis, and has been critical to the clinical success of the Children's Hospital of Philadelphia Thyroid Center.
Dr. Adamson serves as chair of the international consortium Children's Oncology Group and on the National Cancer Advisory Board. In addition to his national and international leadership roles in pediatric oncology, Dr. Adamson maintains a dynamic research program on pediatric clinical-translational drug development, with a strong focus on childhood cancer drug development.
Dr. Diskin's research is focused on translational genomics in childhood cancers. Her laboratory seeks to identify the genetic basis of childhood cancers by combining quantitative computational methods with rigorous "wet-lab" experimental approaches. In parallel, she has developed, and is applying, a proteogenomic approach to identify novel immunotherapeutic targets for high-risk and relapsed pediatric malignancies.